EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSPCIG00000030431
Gene Symbol: SCN2A
1 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSPCIG00000030434
Gene Symbol: SCN3A
1 Cross references
171 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSPCIG00000034956
Gene Symbol: SCN5A
1 Cross references
95 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSPCIG00000012175
Gene Symbol: SCN8A
1 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 10 Member 2

Ensembl ID : ENSPCIG00000018550
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 1

Ensembl ID : ENSPCIG00000011049
Gene Symbol: SLC6A1
1 Cross references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 2

Ensembl ID : ENSPCIG00000003091
Gene Symbol: SLC6A2
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 3

Ensembl ID : ENSPCIG00000029086
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 4

Ensembl ID : ENSPCIG00000022738
Gene Symbol: SLC6A4
1 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 9

Ensembl ID : ENSPCIG00000015602
Gene Symbol: SLC6A9
1 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Somatostatin Receptor 2

Ensembl ID : ENSPCIG00000001992
Gene Symbol: SSTR2
1 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSPCIG00000012131
Gene Symbol: S1PR1
1 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).